Preventing Collateral Damage in the Inflammatory Bowel Disease Patient: Using Disease Assessment and Prognostic Factors to Optimise Clinical Outcomes

This symposium took place on the 17th October 2016, as a part of the United European Gastroenterology (UEG) Week in Vienna, Austria

Chairperson: Laurent Peyrin-Biroulet1
Speakers: Jean-Frédéric Colombel,2 Subrata Ghosh3

1. Department of Gastroenterology and Inserm U954, Nancy University Hospital,
Lorrraine University, Vandoeuvre-lès-Nancy, France
2. Icahn School of Medicine at Mount Sinai, New York City, New York, USA
3. Institute of Translational Medicine, University of Birmingham, Birmingham, UK

Disclosure: Dr Laurent Peyrin-Biroulet has received consulting fees from Merck, AbbVie, Janssen, Genentech, Mitsubishi, Ferring, Norgine, Tillots, Vifor, Therakos, Pharmacosmos, Pilège, BMS, UCB-pharma, Hospira, Celltrion, Takeda, Biogaran, Boerhinger-Ingelheim, Lilly, Pfizer, HAC-Pharma, Index Pharmaceuticals, Amgen, Sandoz, Forward Pharma GmbH, Celgene, Biogen, Lycera, and Samsung Bioepis. He has also received lecture fees from Merck, AbbVie, Takeda, Janssen, Takeda, Ferring, Norgine, Tillots, Vifor, Therakos, Mitsubishi, and HAC-pharma. Dr Jean-Frédéric Colombel has served as consultant, advisory board member, or speaker for AbbVie, Amgen, Boehringer-Ingelheim, Celgene Corporation, Celltrion, Enterome, Ferring, Genentech, Janssen and Janssen, Medimmune, Merck & Co., Pfizer, Protagonist, Second Genome, Seres, Shire, Takeda, Theradiag, and Theravance Biopharma. He has participated in a speaker’s bureau for Amgen, holds stock options from Intestinal Biotech Development and Genfit, and has received research grants from AbbVie, Takeda, and Janssen and Janssen. Dr Subrata Ghosh has participated in international steering committees for AbbVie, Janssen, Pfizer, Celgene, BMS, and Novartis. He has been a speaker for AbbVie, Janssen, and Takeda and has been a member of advisory committees for AbbVie, Janssen, Takeda, Ferring, and Hospira.
Acknowledgements: Writing assistance was provided by ApotheCom, London, UK
Support: The publication of this article was funded by AbbVie. The views and opinions expressed are those of the authors and not necessarily AbbVie.
Citation: EMJ Gastroenterol. 2016;5[1]:28-33.

Meeting Summary

Inflammatory bowel diseases (IBDs) are chronic disabling conditions. Despite the benefits of anti-tumour necrosis factor-α agents in improving quality of life and reducing the need for surgery in many patients, only one-third achieve clinical remission after 1 year of treatment. It is important that treatments go beyond just the alleviation of symptoms, and help to achieve mucosal healing and deep remission.1 The symposium reviewed the natural course of IBD and discussed how focussing management strategies away from simple symptomatic control towards maintaining mucosal healing can significantly improve the quality of life and wider clinical outcomes of patients with IBD. However, this shift in approach requires the redefining of disease severity to highlight the importance of inflammation control and mucosal healing in preventing long-term damage and disability.

Dr Peyrin-Biroulet opened the sessions by reviewing how the Randomised Evaluation of an Algorithm for Crohn’s Treatment (REACT) study has enhanced the understanding of the natural history of IBD, and how complete mucosal healing provides the best outcomes in IBD.2 Dr Colombel highlighted that uncontrolled inflammation in IBD can lead to poor outcomes, and how simple demographic and clinical features can guide the clinician in identifying patients at higher risk for disease complications both at diagnosis and throughout the disease course. Dr Ghosh discussed the importance of defining disease severity in IBD and reinforced that while symptoms related to disease activity are a component of overall disease severity, many factors need to be considered to understand the total impact on a patient’s quality of life.

Download (PDF, 90KB)

Comments are closed.